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Abstract.  We recently characterized three FGF- 
binding proteins (FGF-BPs) which are soluble forms 
of the extracellular domains of the high affinity FGF 
receptors (Hanneken,  A. M., W. Ying,  N. Ling, 
and A. Baird. Proc.  Natl.  Acad.  Sci.  USA.  1994. 
91:9170-9174).  These proteins circulate in blood and 
have been proposed to modulate the biological activity 
of the FGF family of proteins.  Immunohistochemical 
studies now demonstrate that these soluble, truncated 
FGF receptors are also present in the basement mem- 
branes of retinal vascular endothelial cells. These im- 
munoreactive proteins can be detected with antibodies 
raised to the extracellular domain of FGFR-1 but not 
with antibodies raised to either the juxtamembrane do- 
main or the cytoplasmic domain of FGFR-1. Western 
blotting of human retinal extracts with the antibody 
raised to the extracellular domain of FGFR-1 detects 
specific, low molecular mass proteins at 85 kD and 55 
kD, corresponding in size to the FGF-BPs, which are 
not detected with antibodies against the cytoplasmic 
domain of the receptor. 
The interaction of this receptor with the extracellu- 
lar matrix is not dependent on the presence of FGF-2. 
Immunoreactive receptors are still detected in vascular 
basement membranes after the removal of FGF-2 with 
heparitinase.  In addition,  the recombinant extracellular 
domain of FGFRA continues to bind to corneal en- 
dothelial cell matrix after endogenous FGF-2 has been 
removed with 2 M  NaC1.  Acid treatment,  which has 
been shown to disrupt protein interactions with the ex- 
tracellular matrix,  leads to a significant reduction in 
the presence of the matrix form of the FGF receptor. 
This loss can be restored with exogenous incubations 
of the recombinant extracellular domain of FGFR-1. 
This report is the first demonstration that a trun- 
cated form of a high affinity growth factor receptor 
can be localized to the extracellular matrix.  These 
findings add to the list of binding proteins associated 
with the extracellular matrix (IGFBP-5) and suggest a 
potentially new regulatory mechanism for controlling 
the biological availability of FGF, and other peptide 
growth factors, in the extracellular matrix. 
Asxc fibroblast  growth factor (FGF-2) ~ is a heparin- 
binding  growth  factor which  is  widely distributed 
in the basement membranes of many  tissues (4,  6, 
10).  Although  very low quantities  of FGF-2 stimulate  the 
proliferation  of cells in vitro, the vast majority of cells which 
are  surrounded by this  FGF in vivo are quiescent.  This 
highly controlled state suggests that the basement membrane 
stores of FGF-2 are relatively  inert.  Accordingly,  several 
mechanisms  have been proposed to explain  this phenome- 
non:  regulation  by the number of high affinity cell surface 
FGF receptors, release of enzymes by target cells, and post- 
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translational  modification of FGF (1). However, the issue re- 
mains largely  unresolved. 
We recently identified three circulating  FGF-binding pro- 
teins (FGF-BPs) in human and bovine blood. These proteins, 
with molecular masses ranging  from 55-85 kD,  were de- 
tected by searching  for proteins that bind to FGF-heparin 
Sepharose affinity columns and bind to FGF-2 by ligand blot- 
ring (12). Immunoblotting  and protein sequencing data dem- 
onstrate that these proteins are forms of the extracellular  do- 
main  of the  high  affinity  FGF  receptor,  FGF  receptor-1 
(FGFR-1).  Since  the recombinant extracellular  domain of 
FGFR-1  inhibits  the biological properties of FGF-2  (18), 
these circulating FGF-BPs have the potential to modulate the 
biological  activities  of FGF- 2, and other members of the 
FGF gene family, in vivo. 
We show here that a truncated form of an immunoreactive 
high affinity FGF receptor is present in the extracellular  ma- 
trix  of vascular endothelial  cells.  The  interaction  of this 
receptor with the extracellular  matrix is not affected by the 
removal of FGF-2 after beparitinase treatment but is reduced 
by treatment  with 1N acetic acid.  These data suggest that 
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cated form of the FGF receptor in the basement membrane. 
Thus,  an extracellular matrix-bound  receptor may play a 
role in regulating  the biological activities and availability  of 
the FGFs in the basement membrane. 
Materials and Methods 
Antibodies 
A number of different monoclonal antibodies to FGF receptors were used 
in this study. Ab6 is a mouse monocional antibody that was raised against 
the three Ig loop form of  the extracellular domain (ECD) of hnman FGFR-1 
expressed in insect cells (18).  It was purified from ascites by ammonium 
sulfate precipitation and protein A purification (manuscript in preparation). 
It is a  pan-specific FGF receptor antibody that recognizes recombinant 
FGFR-I, FGFR-2, and FGFR-3 and their extracellular domains by Western 
blotting. It recognizes the higher molecular weight FGF receptors on 3T3 
cells and BHK cells, and the 55-kD and 85-kD truncated FGFR-I receptors 
(FGF-BPs) which have been purified and sequenced from bovine calf serum 
(12).  Antibody  50  is  a  mouse  monoclonal  antibody  raised  against  a 
16-amino  acid peptide  (EYELPEDPRWELPRDR)  located  in  the jux- 
tamembrane domain of FGFR-1.  This sequence is well conserved among 
the different members of the FGF receptor gene family.  Ab50 recognizes 
FGFR-1 and R-2 and was a generous gift from the laboratory of Dr. L. R. 
Williams (UCSF,  San Francisco, CA) (3).  Antibody 803  is an affinity- 
purified rabbit polyclonal antibody raised against a  17-amino acid peptide 
sequence (CLPRHPAQLANGGLKRR) located at the carboxyl terminus of 
FGFR-1. The immune serum was passed over a peptid.e affinity column pre- 
pared by conjugating the antigenic peptide to Affigel 102. Affinity-purified 
antibody was eluted from the column with 0.2M HCl-glycine and is specific 
for FGFR-1  (manuscript in preparation). 
Antibodies to heparan sulfate proteoglycan, type IV collagen, and lami- 
nin were purchased from Chemicon (Temeeula, CA), antibodies to Factor 
VIII  related  antigen  were  purchased  from  Dako  Corporation  (Carpin- 
teria, CA). 
Reagents 
A nonglycosylated, three Ig loop form of the ¢xtracellular domain of FGFR-1 
was prepared in E.  coil  The sequence encOding the extracellular domain 
of human FGFR-I was amplified from a plasmid containing the entire cod- 
ing sequence of FGFR-1  (15) using specific primers and the polymerase 
chain reaction. The product was subcloned into the pMAL-p2 vector (New 
England Biolabs., Boston, MA) and the recombinant plasmid used to trans- 
form E. coli. The extracellular domain was expressed and purified accord- 
ing to the manufacturer's instructions. A glycosylated form of the three Ig 
loop form of the extracellular domain of FGFR-1  was expressed in insect 
cells and was a  generous gift from Drs. P. Barr and M.  Kiefer (Chiron 
Corp., Emeryville, CA) (18). 
Cells and Media 
Confluent  adrenal  bovine  capillary  endothelial  (ACE)  were  grown  in 
HDMEM (Gibeo Life Technologies, Inc., Grand Island, NY) with 10% calf 
serum (Hyclone Labs, Logan, UT) and 100 U/nil penicillin, and 100 pg/mi 
streptomycin. Bovine corneal endothelial (BCE) cells were a generous gift 
of Dr. Sandy Feldman (UCSD, San Diego, CA). The cells were maintained 
in DMEM: Nutriem Mixture F-12 1:1 (DMEM/F12; Gibco Life Technolo- 
gies, Inc.) supplemented  with 10% FCS (Hyclone Laboratories) and 15 mM 
Hepes buffer,  100 U/ml penicillin, and  100 ~g/mi streptomycin. 
Immunohistochemistry 
Tissue sections (12/~m) were cut on a cryostat at  -20°C and placed on 
gelatin-conted slides. Sections were fixed in 2% paraformaldehyde for 5 
min,  treated  with  3%  H202,  blocked with  1%  BSA  for 20  min,  and 
processed with the use of  a streptavidin-peroxidase  technique previously de- 
scribed (11). FGF receptor antibodies-(antibodies 6, 50, 803) were used at 
a concentration of 14 t~g/mi and incubated with the sections for 90 vain at 
370C. Controls for the monoclonal antibodies consisted of identical incuba- 
tions with an unrelated hybridoma mouse IgGi (Jackson ImraunoResearch 
Labs., West Grove, PA). Controls for the polyclonal antibody consisted of 
incubations  with  the  unretained  fractions (flowthrough) of the peptide 
affinity purification column. 
Tissue Extractions and Western Blot Analyses 
Human retinas were obtained from autopsy eyes within the first 4-24 h post- 
mortem. Retinas were homogenized at 4°C in 0.32 M sucrose, 10 mM Tris- 
HCI (pH 7.4),  1 mM magnesium chloride (MgCI2),  containing 1 mg/ml 
each leupeptin, aprotinin, and pepstatin A, and 1 mM PMSE The homoge- 
nate was centrifuged at 1,000 g for 5 min to remove nuclei and cell debris. 
The supernatant was spun at  17,500  g  for  15 min.  The pellet was then 
resuspended in homogenization buffer, sonicated, solubilized in Laemmli's 
sample buffer, boiled at 100°C for 5 min, and the proteins separated on a 
7.5 % SDS-polyacrylamide gel. The proteins were transferred to nitrocellu- 
lose (Schleicher and Schuell, Keene, NH) and immunoblotted with 5/~g/ml 
of  Ab6 or Ab50 in Tris- buffered saline (TBS), pH 7.4, with 5 % nonfat milk 
(NFM). After an overnight incubation, the nitrocellulose was washed three 
times with TBS, treated with 1 pg/ml of afffinity-purified rabbit anti-mouse 
IgG 0ackson ImmunoResearch Labs.) in TBS, 5% NFM for 2 h, washed 
three times with TBS, and incubated with 2 pCi of 125I-Protein A  (ICN 
Radiochemicals, Irvine, CA) in 5 % NFM for 2 h. After washing three times 
in TBS, the blots were dried in a 60°C oven, and exposed to XAR5 auto- 
radiographic film (Eastman Kodak, Rochester, NY) at -70°C as indicated. 
Confluent adrenal capillary endothelial cells were washed in cold PBS 
(x2) and solubilized with Laemmli's sample buffer. The proteins were sepa- 
rated on a 7.5 % SDS-polyacrylamide gel and Western blots were performed 
as described above. 
Enzyme Digestions 
Fresh frozen tissue sections were fixed in 2 % paraformaldehyde for 5 min 
and washed three times over 15  rain.  Heparitinase digestions were per- 
formed for 30-60 rain at 37"C using 0.01 IU/slide of heparitinase (ICN Im- 
munoBiologicals, Costa Mesa, CA) prepared in 50 mM Tfis-HCI, 20 mM 
Ca-Acetate, pH 7.4 (13). Collagenase digestions were performed using 0.05 
mg/ml of type IV collngenase (Sigma Chem. Co., St, Louis, MO) prepared 
in PBS, Chondroitinase digestions were performed using 20 U/slide Chow 
droitinase ABC (Sigma Chem. Co.) prepared in PBS with 1 mM Cael, 1 
mM MgCI. The slides were next treated with 3% H202 and incubated with 
Abt, or stained with antibodies to FGF-2 as described (9). Control sections 
were treated with buffer alone. 
Acid Dissociation and Exogenous Binding of the ECD 
to Matrix 
Fresh frozen or 2%  paraformaldehyde fixed sucrose embedded sections 
were cut on a cryostat and air-dried. The slides were treated with 1 N acetic 
acid for 30 rain at room temperature, and then washed with PBS. After acid 
treatment, the sections were fixed in 2 % paraformaldehyde and staining was 
performed according to the protocol outlined above. In some cases, after 
a 20-rain block in 1% BSA, tissue sections were incubated with 10/~g/ml 
nonglycosylated extracellular domain in 1% BSA (to prevent nonspecific 
binding). After five washes with PBS, the sections were incubated with Ab6 
(14/~g/ml). 
Matrix-binding Studies 
Bovine  corneal  endothelial  cell  matrix  was  prepared  by  incubating  a 
confluent plate of BCE cells with 20 mM NI-hOH in H20 according to 
published techniques (8).  The plates were washed with PBS four times 
to remove cell debris. To evaluate the ability of the extracellular domain to 
bind to basement membrane, bovine corneal endothelial cell matrix was in- 
cubated with the insect or E. coli expressed extracellular domain of FGFR-1 
for 30 rain at 37"C at a concentration of 0.5 pg/mi in 1% BSA (to prevent 
nonspecific binding). In some cases, matrix was first treated with 2M NaCI 
at 370C for 30 min to remove FGF-2, and then incubated with the recom- 
binant extracellular domain of FGFR-I in 1% BSA. After the incubations, 
the matrix was washed extensively, solubilized with 2.5  x  sample buffer, 
and the proteins were separated on a 7.5% SDS-polyacrylamide gel, trans- 
ferred to nitrocellulose, and blotted with Ab6 as described above. 
Ligand Blotting 
Ligand blotting was performed by solubilizing 150-300 ng of recombinant 
ECD (prepared in insect cells) in 1×  Laemmli's sample buffer under non- 
reducing conditions. The proteins were separated on an 8 %  SDS-POly- 
acrylamide gel, and transferred to nitrocellulose in a  Ti'is/glycine  trans- 
fer buffer (25  mM Tris base,  190 mM glycine). The nitrocellulose was 
blocked with 5% nonfat milk in TBS (20 mM Tris-HCl/150 mM NaCI, pH 
The Journal  of Cell Biology,  Volume 128, 1995  1222 Figure 1. Vascular basement membrane localization of FGF receptors in human retina.  Twelve micron cryostat sections  of human retina 
were fixed with 2% paraformaldehyde,  incubated with 3% HeO~, blocked with 1% BSA, and processed using a streptavidin  peroxidase 
technique as described in Materials  and Methods. Immunohistochemical localization with antibodies  to (,4) the extracellular  domain of 
FGFR-1, (Ab6); (B) FGF-2 (9); (C) the juxtamembrane domain of FGFR-1, (AbS0);  (D) the carboxyl terminus of FGFR-1, (AbS03);  (E) 
control hybridoma mouse IgGi; and (F) heparan sulfate proteoglycan. Solid black arrows highlight  vascular basement membranes and 
open arrows highlight  neuronal staining.  Note the red reaction product in basement membranes in A-B-F and the absence of basement 
membrane staining  in C-D. 
Hanneken et al. FGF Receptors in Extracellular Matrix  1223 Figure 2. Western blot analysis of FGF receptors in human retina 
and adrenal capillary endothelial (ACE) cells. Tissue and cell ex- 
tracts were prepared as described in Materials and Methods and im- 
munoblotted  using antibodies  to the extracellular  domain of  FGFR-1 
(Ab6, left panel) or antibodies to the juxtamembrane region of 
FGFR-I (Ab50, right  panel). Both antibodies recognize l~gb mo- 
lecular mass bands between 125-140 kD but only Ab6 recognizes 
85 kD and 55 kD proteins in human retina and a 55-60-kD protein 
in ACE ceils. 
7.4) for 30 rain and incubated overnight with 500,000 epm of 125I-FGF-2 
per ml in the presence or absence of  50 #g of  urdabeled recombinant FGF-2, 
The nitrocellulose was then washed five times with TBS and exposed to Ko- 
dak XAR5 film overnight. 
Results 
Localization  of  FGF  Receptor Immunoreactivity to 
Basement Membranes 
While examining the distribution of high affinity  FGF recep- 
tors in the human retina, we observed a consistent pattern 
of staining that was unexpectedly associated with microvas- 
cular basement membranes.  To confirm that this staining 
represented the extracellnlar domain of a high affinity FGF 
receptor,  immunohistoehemical studies were performed with 
three  distinct  antibodies  to  FGFR-1.  Using  an  antibody 
which  recognizes  the  extracellular  domains  of  the  high 
affinity FGF receptors (Ab6), we detected immunoreactive 
FGF receptors in neuronal cells throughout the inner and 
outer retina (Fig.  1 A, open arrows). Remarkably, we also 
detected immunoreactive FGF receptors  in the basement 
membranes of retinal capillary endothelial cells (Fig.  1 A, 
closed arrows). This matrix staining was very similar to the 
patterns observed with antibodies to Factor VI/I and anti- 
bodies to several different basement membrane proteins, in- 
cluding  type  IV  collagen,  laminin,  and  heparan  sulfate 
proteoglycan (Fig.  1 F). Surprisingly, this basement mem- 
brane staining of FGFR was also identical to the basement 
membrane staining of FGF-2 (9), indicating that FGF-2 and 
high affinity FGF receptor irnmunoreactivity colocalize to 
the extracellular matrix (Fig.  I B). 
To determine whether the form of the FGF receptor ira- 
rnunoreactivity in the basement membrane consisted only of 
the extracellular domain of the receptor, we performed im- 
munohistochernical studies using FGF receptor antibodies 
raised to two different regions of the cytoplasmic domain. 
Antibodies raised to the juxtamembrane region (Ab50) and 
the carboxyl terminus  (Ab803)  of the high affinity FGF 
receptors localize immunoreactive FGF receptors to neu- 
ronal cells (open arrows, Fig. 1, C-D),  consistent with the 
cell staining obtained with Ab6.  However, no staining was 
observed in vascular basement membranes with these anti- 
bodies. Thus, vascular basement membranes appear to con- 
tain a form of FGF receptor immunoreactivity which lacks 
the cytoplasmic domain. Mouse IgG (Fig.  1 E) and the flow 
through from the polyclonal affinity column (not shown) 
were both used as negative controls and showed only faint 
background staining. 
Western Blot Analysis with FGF  Receptor Antibodies 
The immunohistochemical  detection of the extracellular do- 
main of a high affinity FGF receptor in microvascular base- 
ment membranes predicts that a low molecular mass form 
of an FGF receptor (50-90 kD) should be detected in ex- 
tracts of retina and capillary endothelial cells. The immuno- 
histochemical studies also predict that the low molecular 
weight FGF receptor will be detected by Ab6,  but not by 
Ab50, because Ab50 does not recognize the extracellular do- 
main of the FGF receptor. As expected, immunobloRing of 
capillary endothelial cells and human retinal extracts with 
Ab6 and Ab50 reveals high molecular mass bands between 
116-140  kD which correspond to the expected sizes of the 
full length, transmembrane high affinity  FGF receptors (Fig. 
2). Only Ab6 detects additional low molecular mass proteins 
at 85 kD and 55 kD in human retinal extracts and 55-60 kD 
proteins in capillary endothelial cell extracts. These proteins 
are similar in size to the FGF-binding proteins which have 
been isolated from blood and shown to be portions of the ex- 
tracellular domain of FGFR-1  (12). 
A 200+ kD band, which is higher than any of  the expected 
molecular masses for high affinity FGF receptors,  is also 
present in the immunohlots with Ab6 and Ab50. The inten- 
sity of  this band varies as a function of the preparation of the 
cells and is thought to represent a high molecular weight ag- 
gregate. A  116-kD band, which is detected by irnmunoblot- 
ring with Ab6 but not with Ab50, is most likely a form of 
FGFR-3 since Ab6 is pan-specific and recognizes FGFR-1, 
FGFR-2, and FGFR-3. In contrast, Ab50 recognizes only 
the cytoplasmic domains of FGFR-1  and FGFR-2. 
Matrix Binding of  FGFR-1 Is Independent of  FGF 
A high degree of cooperative binding appears to exist be- 
tween FGE heparan sulfate, and the FGF receptor (20, 29). 
To determine whether the removal of FGF-2 from basement 
membranes  affects  the  localization of high  affinity FGF 
receptors in basement membranes, we incubated tissue sec- 
tions with beparitinase (which is known to release FGF-2 
from beparan sulfate proteoglycans [10, 13]) before staining 
with Ab6.  Heparitinase treatment abolished the staining of 
FGF-2 in the basement membrane (Fig. 3, A-B), but did not 
reduce the staining of  the FGF receptor (Fig. 3 C). In an un- 
expected  result,  we  found heparitinase  treatment signifi- 
cantly increased the basement membrane staining. Similar 
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traceUular FGF-2. Fresh frozen tissue sections  were fixed in 2 % 
paraformaldehyde  for 5 rain, washed three times over 15 min, and 
(,4) incubated with PBS or (B and C) digested with heparitinase for 
45 rain at 37"C as described in Materials and Methods.  The slides 
were next treated with 3 % H202 and (A and C) incubated with an- 
tibodies to  the  extracellular domain of FGFR-1  (Ab6),  or  (B) 
stained with antibodies to FGF-2, as described in Materials and 
Methods.  Solid  dark  arrows  indicate vascular basement mem- 
branes. Asterisks  indicate FGF receptor localization to neuronal 
cells. Note the increase in FGF receptor immunoreaetivity  in vas- 
cular basement membranes after heparitinase digestion (C) even 
though the intensity of the neuronal staining is similar. The loss of 
basement membrane FGF-2 immunoreactivity is demonstrated in 
Fig.  3 (B). 
Figure 5. Acid dissociation  and exogenous binding  of a recombinant 
form of the extracellular  domain of FGFR-1 to tissues.  12-#m fresh 
frozen or minimally fixed 2% paraformaldehyde-treated  sections 
were treated for 30 rain at room temperature  with (A) PBS or (B 
and C) 1N acetic acid.  The sections were treated with 3 % 1-1202, 
blocked with 1% BSA, and (A and B) stained with Ab6 as described 
in Materials and Methods or (C) incubated  with a I0 #g/ml dilution 
of the recombinant  extraceUular domain of FGFR-I as described in 
Materials  and Methods,  extensively  washed with PBS, and then 
stained with Ab6. 
Hanneken  et al. FGF Receptors in Extracellular Matrix  1225 Figure 4. Binding of  the extraceUular  domain of FGFR-I to bovine 
corneal endothelial (BCE) cell matrix. BCE matrix was immuno- 
blotted with the antibody to the extracellular domain of FGFR-1 
(Ab6) as described in Materials and Methods. The effect of FGF-2 
removal on the binding of FGFR-I was examined by incubating 
recombinant extracellular domain of FGFR-I with BCE matrix 
which had been treated with PBS (lane 2) or 2M NaC1 (lane 3). 
Recombinant extraceUular domain bound to BCE matrix in the 
presence orthe absence of  FGF-2. Lane I demonstrates the low lev- 
els of endogenous FGF receptor in BCE matrix. 
results were obtained in five separate experiments. To show 
that nonspecific degradation of the basement membrane was 
not responsible for this increase in FGF receptor immunore- 
activity, we performed enzymatic digestions with chondroiti- 
nase and collagenase. Neither enzyme changed the intensity 
of FGF receptor staining in the extraceUular matrix (results 
not shown). 
We next examined whether the removal of FGF-2 from bo- 
vine corneal endothelial cell (BCE) matrix would alter the 
binding of the recombinant extracellular domain to the ex- 
tracellular matrix. Although the endogenous level of FGF 
receptors in BCE cell matrix is very low (Fig. 4, lane 1 ), 
after incubating BCE matrix with 500 ng/ml of recombinant 
extracellular domain (in the presence of 1% BSA to elimi- 
nate nonspecific binding), an intense 55-kD band is detected 
in BCE matrix extracts with Ab6 (Fig. 4, lane 2). High mo- 
lecular weight aggregates of the recombinant extracellular 
domain are also present. The signal is not diminished if en- 
dogenous FGF-2 is removed from the matrix with 2M NaC1 
before the addition of the extracellular domain (Fig. 4, lane 
3),  indicating  that  FGF-2  is  not a  requirement for FGF 
receptor binding to the extracellular matrix. These results 
are independent of whether the recombinant extracellular 
domain was produced either in E. coli (non-glycosylated) or 
SF9 cells (glycosylated, not shown). 
Dissociation  of the FGF-2/FGF  Receptor Complex in 
Extracellular Matrix 
Because acid treatment is known to disrupt both the high 
affinity FGF-2/FGF receptor complex and other ionic inter- 
actions with extracellular matrix (19), we examined whether 
acid could disrupt the interaction of high affinity FGF recep- 
tors with the extracellular matrix. We found that FGF recep- 
Figure 6. Ligand blotting of t25I-FGF-2 
to the recombinant extracellular domain 
of FGFR-1. 150 t~g (lane 1 ) and 300/~g 
(lane 2) of the extracellular domain was 
separated on an 8 % SDS-polyacrylamide 
gel under  nonreducing conditions and 
transferred to nitrocellulose  as described 
in Materials and Methods. 500,000 cpm 
of 125I-FGF-2 per ml was added to the 
nitrocellulose overnight. 
tor immunoreactivity was nearly eliminated from the base- 
ment membranes after acid washing (Fig. 5, A-B). However, 
this basement membrane staining could be restored by in- 
cubating the acid-treated sections with the recombinant ex- 
tracellular domain (in the presence of 1% BSA to eliminate 
nonspecific binding). (Fig. 5 C) We found the effect of acid 
treatment was specific for FGF receptors, since the immuno- 
histochemical localization of all other antigens present in 
vascular basement membranes (Factor VIII, Type IV colla- 
gen, and heparan sulfate proteoglycan) was completely unaf- 
fected  by acid treatment (not shown). The structural integrity 
of the tissues was also unaffected by this acid treatment. 
Ligand Blotting of the Recombinant Extracellular 
Domain of FG  FR-1 
The  above  studies  demonstrate  that  the  recombinant  ex- 
tracellular domain is capable of binding to extracellular ma- 
trix of vascular endothelial cells.  To demonstrate that the 
recombinant extracellular domain of FGFR-1 is capable of 
binding FGF-2, we performed ligand blotting. We found that 
t2SI-FGF-2 binds  to the recombinant extracellular domain 
in a dose-dependent manner (Fig. 6), and this binding could 
be eliminated in the presence of excess nonradioactive FGF-2 
(not shown). 
Discussion 
This study demonstrates that a form of the high affinity FGF 
receptor is present in the extracellular matrix of vascular en- 
dothelial cells. This finding is supported by the facts that (a) 
the  matrix  staining  localizes  to  capillary-like  structures 
throughout the inner retina, consistent with the anatomical 
distribution of the retinal vasculature,  (b) the localization 
matches the pattern obtained with Factor VIII-related anti- 
gen, as well as antibodies to the basement membrane com- 
ponents type IV collagen, heparan sulfate proteoglycan, and 
laminin, and (c) the pattern is identical to the matrix local- 
ization of FGF-2 (9). Of course, unequivocal confirmation 
of the matrix localization of FGFR-1 awaits the results of EM 
localization. 
Our  data  also  suggest  that  the  immunoreactive,  high 
affinity FGF receptor that is present in the matrix lacks the 
The Journal of Cell Biology, Volume 128,  1995  1226 cytoplasmic domain of  the receptor. These data are based on 
the immunohistochemical-staining patterns  obtained with 
three  distinct FGF receptor  antibodies  (Ab6,  Ab50,  and 
Ab803)  that recognize different epitopes in either the ex- 
tracellular or cytoplasmic domains of the FGF receptor. All 
three  antibodies  recognize  neuronal  cell-associated  FGF 
receptors in human retina. The two antibodies which immu- 
noblot recognize high molecular protein bands with sizes 
characteristic of full-length, high affinity  FGF receptors (16, 
27). Only the antibody to an epitope in the extracellular do- 
main shows matrix staining and detects 85-kD and 55-kD 
proteins in retinal and endothelial cell extracts. These pro- 
teins are similar in size to two low molecular weight, high 
affinity FGF receptors (FGF-BPs) which have recently been 
identified in bovine and human blood. Peptide sequencing of 
the amino terminus of the 55-kD and 85-kD FGF-BP show 
they are identical to the amino terminus of the two Ig loop 
form of FGFR-1  (12). Thus, the FGF receptors detected in 
matrix and identified in blood are both presumably the trun- 
cated forms of the high affinity FGF receptor.  A  formal 
confirmation of the  identity of these  proteins  awaits  the 
results of ongoing extracellular matrix purification studies. 
Although the cellular source of the matrix-associated im- 
munoreactivity is not known, the intense 55-kD band in the 
Western blots of capillary endothelial cells (Fig. 2) suggests 
that the vascular endothelial cells may synthesize this protein 
and deposit it into their basement membranes. Vascular en- 
dothelial ceils may also be the source of the soluble FGF 
receptors which have been detected in blood. In support of 
this  hypothesis,  an  mRNA  encoding a  secreted  form of 
FGFR-1  (16) was detected in extracts of human umbilical 
vein  endothelial  cells  (3).  It  remains  to  be  determined 
whether these matrix receptors are specific, secreted forms 
of the receptor or are generated by cleavage of the full-length 
transmembrane receptor. 
The heparitinase studies indicate that the binding of FGF 
receptors to the extracellular matrix is, at least partially, in- 
dependent of the presence  of FGF-2 and heparan  sulfate 
glycosaminoglycans. Surprisingly, instead of a marked de- 
crease in matrix receptor immunoreactivity after the release 
of FGF-2, we detected a striking increase in the matrix sig- 
nal. This effect is highly reproducible, is specific for hepari- 
tinase, and cannot be reproduced with other enyzme treat- 
ments. Because this effect is not seen in neuronal cells, and 
is only detected in the matrix, it is unlikely to be an artifact 
due to the consequences of enzymatic treatment of the tissue 
sections. Presumably, this effect is due to improved accessi- 
bility of the FGF receptor antibody for its antigen after the 
specific removal of FGF-2 and glycosaminoglycans  from the 
basement membrane. Once the specific isoform of the matrix 
FGF receptor has been identified from the numerous poten- 
tial isoforms (14), it will be possible to examine the binding 
of this receptor to specific components of the extracellular 
matrix and to elucidate the nature of this interaction. 
Although low affinity receptors for FGF-2 and TGF-/3 and 
binding proteins for other growth factors have been iden- 
tiffed in basement membranes (2,  4,  17, 22,  26 28),  this 
is  the  first  demonstration  of a  high  affinity cell  surface 
growth factor receptor in the extracellular matrix. The role 
that it plays in FGF function is not known, but it is interesting 
to speculate that it modulates the interaction between FGF-2 
and signal-transducing cell surface receptors. This may help 
explain why the proliferation of FGF target cells is so low 
in vivo despite the presence of FGF-2 in the adjacent base- 
ment membranes. We now suggest that the matrix stores of 
FGF-2 are sequestered by both low affinity heparan sulfate 
proteoglycans and truncated high affinity FGF receptors. In 
order for matrix stores of FGF-2 to bind to the FGF recep- 
tors on adjacent cells, they must be released from these high 
affinity receptors in the matrix. The finding that acid treat- 
ment of matrix eliminates the matrix receptor staining sup- 
ports this hypothesis. For example, in the acidic environment 
of wound fluids, the presence of endogenous FGF-2 will be 
revealed to the target cell by its dissociation from the recep- 
tor in the matrix. Protected from degradation by its interac- 
tion with heparin (23, 24), FGF would then be free to pro- 
mote angiogenesis and wound healing. 
Many cytokines, including IL-7, GM-CSF, IL-5, G-CSF, 
and NGF, have truncated receptors which are capable of 
blocking cell surface binding to high affinity receptors (5, 7, 
21, 25, 30).  However,  none of these receptors has been de- 
tected in  the  extracellular matrix.  The presence  of high 
affinity FGF receptors in the extracellular matrix suggests a 
potential regulatory mechanism to restrict the potent biolog- 
icai activities of the FGF family. 
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